Model | IDI (95%CI) | P | NRI (95%CI) | P |
---|---|---|---|---|
Cancer-specific survival | ||||
 Model 1 (NPLN) | −0.006 (−0.010 to −0.002) | < 0.001 | −0.000 (−0.054 to 0.029) | 0.884 |
 Model 2 (LODDS) | −0.006 (−0.009 to −0.003) | < 0.001 | −0.119 (−0.160 to 0.016) | 0.093 |
 Model 3 (LNR) | −0.002 (−0.004 to −0.000) | < 0.001 | −0.094 (−0.125 to −0.068) | < 0.001 |
 Model 4 (LODDS+LNR) | Reference |  | Reference |  |
Overall survival | ||||
 Model 1 (NPLN) | −0.008 (−0.013 to −0.005) | < 0.001 | −0.111 (−0.132 to −0.050) | < 0.001 |
 Model 2 (LODDS) | −0.006 (−0.010 to −0.004) | < 0.001 | −0.067 (−0.131 to 0.039) | 0.266 |
 Model 3 (LNR) | −0.001 (−0.003 to −0.000) | < 0.001 | −0.088 (−0.136 to −0.066) | < 0.001 |
 Model 4 (LODDS+LNR) | Reference |  | Reference |  |